Browse medicines, page 4 of 6
Some records contain detailed evidence; others currently contain only basic identity and regulatory information. Reviewed conclusions appear only when they are available for a specific use and group of people.
Showing 181–240 of 319 records
Collagenase Clostridium Histolyticum (Xiaflex / Collagenase Santyl)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Dupuytren’s contracture with a palpable cord
Corticorelin Ovine Triflutate (Acthrel)
Protein medicineApproved in the United States (FDA)Expanded recordCosibelimab-Ipdl (Unloxcyt)
Protein medicineApproved in the United States (FDA)Expanded recordDatopotamab Deruxtecan-Dlnk (Datroway)
Protein medicineApproved in the United States (FDA)Expanded recordDenosumab-Bmwo (Osenvelt / Stoboclo)
Protein medicineApproved in the United States (FDA)Expanded recordEculizumab-Aagh (Epysqli)
Protein medicineApproved in the United States (FDA)Expanded recordEfbemalenograstim Alfa-Vuxw (Ryzneuta)
Protein medicineApproved in the United States (FDA)Expanded recordElosulfase alfa (Vimizim)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Mucopolysaccharidosis type IVA (MPS IVA
Emapalumab-Lzsg (Gamifant)
Protein medicineApproved in the United States (FDA)Expanded recordEtanercept-Szzs (Erelzi)
Protein medicineApproved in the United States (FDA)Expanded recordEtanercept-Ykro (Eticovo)
Protein medicineApproved in the United States (FDA)Expanded recordEvinacumab-Dgnb (Evkeeza)
Protein medicineApproved in the United States (FDA)Expanded recordFilgrastim-Sndz (Zarxio)
Protein medicineApproved in the United States (FDA)Expanded recordInebilizumab-Cdon (Uplizna)
Protein medicineApproved in the United States (FDA)Expanded recordInfliximab-Dyyb (Zymfentra / Inflectra)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
ZYMFENTRA is a tumor necrosis factor (TNF) blocker indicated in adults for maintenance treatment of: moderately to severely active ulcerative colitis following treatment with an infliximab product administered intravenously. ( 1 ) moderately to severely active Crohn’s disease following with an infliximab products administered intraneously. ( 1 ) ZYMFENTRA is indicated in adults for maintenance treatment of: moderately to severely active ulcerative colitis following treatment with an infliximab product administered intravenously.
Insulin Glargine-Aldy (Langlara)
Protein medicineApproved in the United States (FDA)Expanded recordInsulin Icodec (Awiqli)
Protein medicineApproved in the United States (FDA)Expanded recordInterferon Alfa-2b (Intron A)
Protein medicineApproved in the United States (FDA)Expanded recordInterferon Beta-1a (Rebif / Avonex / Rebif Rebidose)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
REBIF is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. Rebif is an interferon beta indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. ( 1 )
Interferon Beta-1b (Betaseron)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
BETASERON is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. BETASERON is an interferon beta indicated for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. ( 1 )
Interferon Gamma-1b (Actimmune / Guna-Inf gamma)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Reducing the frequency and severity of serious infections associated with Chronic Granulomatous Disease
Isatuximab-Irfc (Sarclisa / Sarclisa Escena)
Protein medicineApproved in the United States (FDA)Expanded recordLebrikizumab-Lbkz (Ebglyss)
Protein medicineApproved in the United States (FDA)Expanded recordLerodalcibep-Liga (Lerochol)
Protein medicineApproved in the United States (FDA)Expanded recordLinvoseltamab-Gcpt (Lynozyfic)
Protein medicineApproved in the United States (FDA)Expanded recordMarstacimab-Hncq (Hympavzi)
Protein medicineApproved in the United States (FDA)Expanded recordMoxetumomab Pasudotox-Tdfk (Lumoxiti)
Protein medicineApproved in the United States (FDA)Expanded recordOcrelizumab and Hyaluronidase-Ocsq (Ocrevus Zunovo)
Protein medicineApproved in the United States (FDA)Expanded recordOmalizumab-Igec (Omlyclo)
Protein medicineApproved in the United States (FDA)Expanded recordPegaspargase (Oncaspar)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
ALL and hypersensitivity to native forms of L-asparaginase
Pegfilgrastim-Pccg (Ennumo)
Protein medicineApproved in the United States (FDA)Expanded recordPeginterferon Alfa-2b (Pegintron / Sylatron)
Protein medicineApproved in the United States (FDA)Expanded recordPertuzumab-Dpzb (Poherdy)
Protein medicineApproved in the United States (FDA)Expanded recordRanibizumab-Hkdz (Ranluspec)
Protein medicineApproved in the United States (FDA)Expanded recordSacrosidase (Sucraid)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Sucrase deficiency, which is part of congenital sucrase-isomaltase deficiency
Technetium Tc-99m Albumin Aggregated Kit (Pulmolite / Macrotec)
Protein medicineApproved in the United States (FDA)Expanded recordTelisotuzumab Vedotin-Tllv (Emrelis)
Protein medicineApproved in the United States (FDA)Expanded recordUstekinumab-Srlf (Imuldosa)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Adults and pediatric patients 6 years of age and older with moderate to severe plaque psoriasis who are candidates for phototherapy or syste
Zolbetuximab-Clzb (Vyloy)
Protein medicineApproved in the United States (FDA)Expanded recordChloramphenicol (Chloromycetin / Chloramphenicol Sodium Succinate / Econochlor / Chlorofair / Mychel-S / Mychel)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Temporarily relieves discomfort due to kidney issues, including occasional frequent urination, foamy urine, headaches, increased blood pressure levels, increased tiredness, itching, lower back discomfort, nausea, loss of appetite, vomiting, need to urinate at night, muscle twitching, and cramps.* *CLAIMS BASED ON TRADITIONAL HOMEOPATHIC PRACTICE, NOT ACCEPTED MEDICAL EVIDENCE, NOT FDA EVALUATED. This product is not intended to diagnose, treat, cure, or prevent any disease.
Desoxyribonuclease (Elase-Chloromycetin)
Protein medicineApproved in the United States (FDA)Expanded recordDornase alfa (Pulmozyme)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Cystic fibrosis (CF) to improve pulmonary function
Lonapegsomatropin-Tcgd (Skytrofa)
Protein medicineApproved in the United States (FDA)Expanded recordMecasermin Rinfabate Recombinant (Iplex)
Protein medicineApproved in the United States (FDA)Expanded recordMethoxy Polyethylene Glycol-Epoetin beta (Mircera)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Anemia associated with chronic kidney disease
Mirikizumab-Mrkz (Omvoh)
Protein medicineApproved in the United States (FDA)Expanded recordMosunetuzumab-Axgb (Lunsumio Velo / Lunsumio)
Protein medicineApproved in the United States (FDA)Expanded recordNatalizumab-Sztn (Tyruko)
Protein medicineApproved in the United States (FDA)Expanded recordNaxitamab-Gqgk (Danyelza)
Protein medicineApproved in the United States (FDA)Expanded recordOcriplasmin (Jetrea)
Protein medicineApproved in the United States (FDA)Expanded recordOlipudase Alfa-Rpcp (Xenpozyme)
Protein medicineApproved in the United States (FDA)Expanded recordPancrelipase (Zenpep / Pancreaze / Creon / Pertzye / Viokace / Cotazym)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
HOMEOPATHIC INDICATIONS: For the temporary relief of symptoms related to leaky gut syndrome such as fatigue, seasonal allergies, joint pain, occasional constipation, mental fogginess and occasional diarrhea.** **These statements are based upon homeopathic principles. They have not been reviewed by the Food and Drug Administration.
Pegfilgrastim-Cbqv (Udenyca)
Protein medicineApproved in the United States (FDA)Expanded recordPegvaliase-Pqpz (Palynziq)
Protein medicineApproved in the United States (FDA)Expanded recordRozanolixizumab-Noli (Rystiggo)
Protein medicineApproved in the United States (FDA)Expanded recordSomapacitan-Beco (Sogroya)
Protein medicineApproved in the United States (FDA)Expanded recordSomatrogon-Ghla (Ngenla)
Protein medicineApproved in the United States (FDA)Expanded recordTeplizumab-Mzwv (Tzield)
Protein medicineApproved in the United States (FDA)Expanded recordTildrakizumab-Asmn (Ilumya)
Protein medicineApproved in the United States (FDA)Expanded recordUstekinumab-Kfce (Yesintek)
Protein medicineApproved in the United States (FDA)Expanded record